In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until disease progression or even the participants are unable to tolerate the study drugs. There may be larger treatment load for members With this trial compared to https://hansw110jvf3.blogs100.com/profile